SRP-9001

DMD

Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm

Fierce Biotech

Wed, 05/3/23 - 11:39 am

Go or no go? Sarepta’s gene therapy faces scrutiny

EP Vantage

Thu, 04/27/23 - 10:29 am

FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy

BioSpace

Fri, 03/17/23 - 10:13 am

Duchenne muscular dystrophy: major trials and events to watch in 2023

Clinical Trials Arena

Thu, 03/16/23 - 09:49 am

DMD

Sarepta's DMD gene therapy inches closer to market as FDA declines to hold advisory meeting

Fierce Biotech

Wed, 03/1/23 - 09:52 am

Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal

Endpoints

Thu, 01/5/23 - 04:58 pm

CDMOs

Catalent

FDA grants speedy review to Sarepta’s Duchenne gene therapy

BioPharma Dive

Tue, 11/29/22 - 10:50 am

Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod

Fierce Biotech

Thu, 11/3/22 - 11:56 am

Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy

BioPharma Dive

Thu, 09/29/22 - 07:38 pm

Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy

BioSpace

Thu, 08/4/22 - 10:59 am

Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy

Fierce Biotech

Fri, 07/29/22 - 10:20 am

Roche

accelerated approvals

Myocarditis case mars Sarepta DMD gene therapy readout

Pharmaforum

Thu, 07/7/22 - 10:23 am

myocarditis

Sarepta says early filing for DMD gene therapy may be back on

Pharmaforum

Wed, 01/12/22 - 10:53 am

Sarepta's second-gen Duchenne drug shows signs of topping its first

BioPharma Dive

Mon, 05/3/21 - 10:54 pm

Is Sarepta Therapeutics Worthy of Redemption?

Motley Fool

Fri, 04/2/21 - 10:52 am

Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock

Fierce Biotech

Fri, 01/8/21 - 09:30 am

clinical trials

New data bolsters Sarepta gene therapies for two deadly muscle diseases

Biopharma Dive

Mon, 09/28/20 - 10:45 am

Limb Girdle Muscular Dystrophy

SRP-9003

Sarepta shares fall on potential regulatory delay for experimental Duchenne drug

Marketwatch

Thu, 09/10/20 - 10:21 am

Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

Xconomy

Tue, 12/24/19 - 12:00 am

Roche